Adjuvant Icotinib Improves DFS vs Chemotherapy in Stage IIV–IIIA EGFR-Mutant NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Icotinib Versus Chemotherapy as Adjuvant Treatment for Stage II-IIIA EGFR-Mutant Non-Small-Cell Lung Cancer (EVIDENCE): A Randomised, Open-Label, Phase 3 Trial
Lancet Respir Med 2021 Jul 16;[EPub Ahead of Print], J He, C Su, W Liang, S Xu, L Wu, X Fu, X Zhang, D Ge, Q Chen, W Mao, L Xu, C Chen, B Hu, G Shao, J Hu, J Zhao, X Liu, Z Liu, Z Wang, Z Xiao, T Gong, W Lin, X Li, F Ye, Y Liu, H Ma, Y Huang, J Zhou, Z Wang, J Fu, L Ding, L Mao, C ZhouFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.